PARP1 and ovarian carcinoma: The positive findings from subsequent trials in ovarian and breast cancer patients, led FDA to approve two more PARP inhibitors for clinical use in patients with BRCA-mutant ovarian cancer: Rucaparib [96] and Niraparib [97] (Table 3).